Castelnau Le Lez, France Clinical Trials

A listing of Castelnau Le Lez, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 8 clinical trials
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer

Institut R gional du Cancer de Montpellier
 (3.3 away) Contact site
  • 25 May, 2021
  • +33 other locations
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer. The study plans to enroll 60 patients with the age of at least 18 years and suffering from prostate …

Institut du Cancer de Montpellier - Val d'Aurelle
 (1.9 away) Contact site
  • 02 Aug, 2021
  • +15 other locations
A Dose Finding and Safety Study of CC-220 Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to …

monoclonal antibodies
measurable disease
CHU Montpellier - H pital Saint Eloi
 (1.9 away) Contact site
  • 19 Jul, 2021
  • +19 other locations
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and …

anticoagulant therapy
Hopital Arnaud de Villeneuve
 (2.2 away) Contact site
  • 11 Jul, 2021
  • +40 other locations
A Study of ABBV-927 and ABBV-181 an Immunotherapy in Participants With Advanced Solid Tumors

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Institut Regional du Cancer /ID# 163609
 (3.0 away) Contact site
  • 28 Jan, 2021
  • +26 other locations
A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.

cancer chemotherapy
neutrophil count
Institut du Cancer de Montpellier
 (3.0 away) Contact site
  • 14 May, 2021
  • +6 other locations
Capecitabine Irinotecan and Oxaliplatin in Treating Patients With Metastatic Cancer

RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I trial …

combination chemotherapy
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
 (1.9 away) Contact site
  • 07 Nov, 2020
  • 1 location
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

measurable disease
hematologic malignancy
mantle cell lymphoma
anti-cd20 antibody
Chu Montpellier, Hematologie Clinique St. Eloi
 (2.2 away) Contact site
  • 31 Mar, 2021
  • +17 other locations